Skip to main content
. Author manuscript; available in PMC: 2022 May 23.
Published in final edited form as: Clin Cancer Res. 2022 May 2;28(9):1841–1853. doi: 10.1158/1078-0432.CCR-21-1242

Figure 5. Longitudinal cfDNA monitoring in cancer patients who received treatments.

Figure 5.

The lines show the tumor fraction in cfDNA during treatment. (a) Tumor fraction in plasma samples of 8 NSCLC patients who received anti-PD-1 immunotherapy. (b) Tumor fraction in serum samples of 4 ovarian cancer patients. (c) Tumor fraction in plasma samples of 12 prostate cancer patients.